Shattuck Labs, Inc. Capital Expenditures Incurred but Not yet Paid
Shattuck Labs, Inc. (STTK) reported Capital Expenditures Incurred but Not yet Paid of $63.00 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-07.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2026-05-07
- Shattuck Labs, Inc. capital expenditures incurred but not yet paid for the quarter ending 2026-03-31 was $63.00K.
- Shattuck Labs, Inc. capital expenditures incurred but not yet paid for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- Shattuck Labs, Inc. capital expenditures incurred but not yet paid for the quarter ending 2025-03-31 was $0.00.
- Shattuck Labs, Inc. capital expenditures incurred but not yet paid for the quarter ending 2024-06-30 was $10.00K.
- Shattuck Labs, Inc. capital expenditures incurred but not yet paid for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Shattuck Labs, Inc. capital expenditures incurred but not yet paid for fiscal 2023 was $71.00K.
- Shattuck Labs, Inc. capital expenditures incurred but not yet paid for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- Shattuck Labs, Inc. capital expenditures incurred but not yet paid for fiscal 2021 was $392.00K, a 13.66% decline from fiscal 2020.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|
| 2026-03-31 | $63.00K 10-Q · filed 2026-05-07 | |||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $0.00 10-Q · filed 2025-08-14 | ||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | $0.00 10-K · filed 2025-03-27 | |||
| 2024-06-30 | $10.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $10.00K 10-Q · filed 2025-08-14 | $81.00K derived: sum of 3 quarters · filed 2025-08-14 | $66.00K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-02 | $71.00K derived: sum of 2 quarters · filed 2025-03-27 | $56.00K derived: sum of 3 quarters · filed 2025-03-27 | -$84.00K derived: sum of 4 quarters · filed 2025-03-27 |
| 2023-12-31 | $71.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $56.00K derived: sum of 2 quarters · filed 2025-03-27 | -$84.00K derived: sum of 3 quarters · filed 2025-03-27 | $71.00K 10-K · filed 2025-03-27 |
| 2023-09-30 | -$15.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$155.00K derived: sum of 2 quarters · filed 2024-08-01 | $0.00 10-Q · filed 2023-11-09 | -$221.00K derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-06-30 | -$140.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $15.00K 10-Q · filed 2024-08-01 | -$206.00K derived: sum of 3 quarters · filed 2024-08-01 | -$169.00K derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-03-31 | $155.00K 10-Q · filed 2024-05-02 | -$66.00K derived: sum of 2 quarters · filed 2024-05-02 | -$29.00K derived: sum of 3 quarters · filed 2024-05-02 | -$164.00K derived: sum of 4 quarters · filed 2024-05-02 |
| 2022-12-31 | -$221.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$184.00K derived: sum of 2 quarters · filed 2024-02-29 | -$319.00K derived: sum of 3 quarters · filed 2024-02-29 | $0.00 10-K · filed 2024-02-29 |
| 2022-09-30 | $37.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$98.00K derived: sum of 2 quarters · filed 2023-11-09 | $221.00K 10-Q · filed 2023-11-09 | -$38.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$135.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $184.00K 10-Q · filed 2023-08-10 | -$75.00K derived: sum of 3 quarters · filed 2023-08-10 | $420.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $319.00K 10-Q · filed 2023-05-09 | $60.00K derived: sum of 2 quarters · filed 2023-05-09 | $555.00K derived: sum of 3 quarters · filed 2023-05-09 | $711.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$259.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $236.00K derived: sum of 2 quarters · filed 2023-02-23 | $392.00K derived: sum of 3 quarters · filed 2023-02-23 | $392.00K 10-K · filed 2023-02-23 |
| 2021-09-30 | $495.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $651.00K derived: sum of 2 quarters · filed 2022-11-09 | $651.00K 10-Q · filed 2022-11-09 | $1.10M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $156.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $156.00K 10-Q · filed 2022-08-11 | $610.00K derived: sum of 3 quarters · filed 2022-08-11 | $610.00K derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $0.00 10-Q · filed 2022-05-12 | $454.00K derived: sum of 2 quarters · filed 2022-05-12 | $454.00K derived: sum of 3 quarters · filed 2022-05-12 | |
| 2020-12-31 | $454.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $454.00K derived: sum of 2 quarters · filed 2022-03-15 | $454.00K 10-K · filed 2022-03-15 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $0.00 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | $0.00 10-Q · filed 2021-08-12 | |||
| 2019-12-31 | $0.00 10-K · filed 2021-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |